TCR cell therapies vanquish solid tumors — finally

The FDA’s approval of the first genetically modified T cell therapy for treating a rare sarcoma is paving the way for next-generation therapies that tackle other types of solid tumors.

Saved in:
Bibliographic Details
Published in:Nature biotechnology 2024-10, Vol.42 (10), p.1477-1479
Main Author: Harrison, Charlotte
Format: Article
Language:English
Subjects:
Agriculture
Bioinformatics
Biomedical and Life Sciences
Biomedical Engineering/Biotechnology
Biomedicine
Biotechnology
Cell therapy
Genetic modification
Humans
Immunotherapy, Adoptive
Life Sciences
Lymphocytes
Lymphocytes T
Neoplasms - immunology
Neoplasms - therapy
News
Receptors, Antigen, T-Cell - genetics
Receptors, Antigen, T-Cell - immunology
Receptors, Antigen, T-Cell - therapeutic use
Sarcoma
Solid tumors
T-Lymphocytes - immunology
Tumors
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The FDA’s approval of the first genetically modified T cell therapy for treating a rare sarcoma is paving the way for next-generation therapies that tackle other types of solid tumors.
ISSN:1087-0156
1546-1696
1546-1696
DOI:10.1038/s41587-024-02435-5